Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.

[1]  Shona Morrison,et al.  Outcomes of women diagnosed and treated for low‐risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC) , 2017, The Australian & New Zealand journal of obstetrics & gynaecology.

[2]  J. Chen,et al.  Bleeding from gestational trophoblastic neoplasia: embolotherapy efficacy and tumour response to chemotherapy. , 2017, Clinical radiology.

[3]  Jun Zhao,et al.  Fertility-sparing uterine lesion resection for young women with gestational trophoblastic neoplasias: single institution experience , 2017, Oncotarget.

[4]  L. Havrilesky,et al.  Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? , 2015, Gynecologic oncology.

[5]  R. Coleman,et al.  Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. , 2016, Gynecologic oncology.

[6]  A. Gadducci,et al.  Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. , 2016, Anticancer research.

[7]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[8]  P. Hanjani,et al.  Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial , 2016, International Journal of Gynecologic Cancer.

[9]  R. Berkowitz,et al.  Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  R. Berkowitz,et al.  Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. , 2015, Gynecologic oncology.

[11]  A. Swerdlow,et al.  Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Seckl,et al.  A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom. , 2015, Gynecologic oncology.

[13]  M. Hasanzadeh,et al.  Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia. , 2014, Journal of cancer research and therapeutics.

[14]  R. Coleman,et al.  The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. , 2013, European journal of cancer.

[15]  N. Sebire,et al.  Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Gilani,et al.  The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. , 2013, Journal of cancer research and therapeutics.

[17]  N. Sebire,et al.  Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 , 2012, British Journal of Cancer.

[18]  A. Baptista,et al.  Comparison of methotrexate, actinomycin D, and etoposide for treating low‐risk gestational trophoblastic neoplasia , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  M. Thomas,et al.  Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia. , 2012, The Journal of reproductive medicine.

[20]  A. Rademaker,et al.  Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. , 2012, Gynecologic oncology.

[21]  R. Berkowitz,et al.  A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. , 2012, The Journal of reproductive medicine.

[22]  R. Berkowitz,et al.  Current management of gestational trophoblastic neoplasia. , 2012, Hematology/oncology clinics of North America.

[23]  H. Shojaei,et al.  Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  Y. Xiang,et al.  Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  W. Kang,et al.  Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. , 2010, Gynecologic oncology.

[26]  S. Wilailak,et al.  Actinomycin D Versus Methotrexate-Folinic Acid as the Treatment of Stage I, Low-Risk Gestational Trophoblastic Neoplasia: A Randomized Controlled Trial , 2009, International Journal of Gynecologic Cancer.

[27]  G. Chalouhi,et al.  Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. , 2009, American journal of obstetrics and gynecology.

[28]  Z. Sarraf,et al.  Weekly intramuscular methotrexate in the treatment of low-risk gestational trophoblastic neoplasia , 2009, Archives of Gynecology and Obstetrics.

[29]  D. Tiezzi,et al.  Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. , 2008, Gynecologic oncology.

[30]  M. Burlea,et al.  [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital]. , 2008, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[31]  Yin Sun,et al.  [Factors related to recurrence of choriocarcinoma and evaluation of treatment outcomes]. , 2006, Zhonghua fu chan ke za zhi.

[32]  R. Coleman,et al.  Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects , 2003, British Journal of Cancer.

[33]  FIGO staging for gestational trophoblastic neoplasia 2000 , 2002 .

[34]  R. Klausner,et al.  Perspective from the National Cancer Institute (NCI). , 1998, Breast disease.

[35]  J. Weed,et al.  The role of operation in the current therapy of gestational trophoblastic disease. , 1980, American journal of obstetrics and gynecology.